Table 4 Severe exacerbations in the previous year and after treatment initiation with benralizumab

Severe exacerbations, mean (SD)

4.4 (2.9)

1.9 (1.2)

Annual rate of severe exacerbations

 Rate per patient-year

3.89

1.77

 Difference

2.12

 CI 95%

0.99–3.24

 p-value*

0.002

Number of exacerbations, n (%)

 0

3 (11.1)

10 (52.6)

 1

2 (7.4)

5 (26.3)

 2

6 (22.2)

1 (5.3)

 ≥ 3

16 (59.3)

3 (15.8)

Category of exacerbation, n (%)

 OCS Bursts/dose increasing ≥ 3 days

24 (88.9)

8 (42.1)

 Hospital admission

5 (18.5)

2 (10.5)

 ED visit

9 (33.3)

5 (26.3)

Annual rate per category of exacerbation

 OCS bursts/dose increasing ≥ 3 days

  Rate per patient-year

3.93

1.46

  Difference

2.47

  CI 95%

1.40–3.54

  p-value*

< 0.001

 Hospital admission requirement

  Rate per patient-year

0.37

0.21

  Difference

0.16

  CI 95%

− 0.21–0.53

  p-value*

0.707

 ED visit requirement

  Rate per patient-year

1.41

0.52

  Difference

0.89

  CI 95%

0.25–1.53

  p-value*

0.034